Meta AnalysisID 7224
二线治疗选择（静脉氨茶碱 vs. 静脉短效β2受体激动剂 vs. 静脉硫酸镁 vs. 皮下注射肾上腺素）用于儿童和青少年急性严重哮喘发作：随机对照试验的系统评价和Meta分析
CRD42023405226
To assess the safety and efficacy of IV aminophylline versus, IV SABA, versus IV magnesium sulphate, versus SC adrenaline, as a second line treatment in acute severe asthma exacerbation in children and adolescents aged 1
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Ingredient: 1Meta-analysis: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final meta_analysis record.
- Meta Analysis Id
- 7224
- Evidence Id
- 15782
- Core Evidence Id
- 15782
- Source Meta Analysis Id
- 7210
- Herb2 Meta Analysis Id
- HBMA007210
- Crd Id
- CRD42023405226
- Title
- Second line treatment options (IV aminophylline, versus IV short-acting-beta2-agonist (SABA), versus IV magnesium sulphate, versus SC adrenaline) for children and adolescents with an acute severe asthma exacerbation: a systematic review and meta-analyses of randomized controlled trials
- Review Question
- To assess the safety and efficacy of IV aminophylline versus, IV SABA, versus IV magnesium sulphate, versus SC adrenaline, as a second line treatment in acute severe asthma exacerbation in children and adolescents aged 18 years and under.
- Study Type Included
- We will include only randomized controlled trials in this review. We will apply no language restriction, and we will undertake English translation of relevant studies if needed.
- Condition Being Studied
- This is one of a series of systematic reviews commissioned by the World Health Organization (WHO) to inform consolidated recommendations for the management of common childhood illnesses. The recommendations will update the existing guidance in the pocket book of hospital care for children and Integrated management of childhood illness (IMCI) charts. The evidence regarding the use of second line treatment options (IV aminophylline versus, IV SABA, versus IV magnesium sulphate, versus SC adrenaline) is limited. Travers et al. found limited evidence for the safety and efficacy of the use of Intravenous SABAs namely terbutaline and salbutamol. These included earlier reductions in the need for recurrent SABA use, no reductions in lengths of ICU admission or length of hospitalization. However, a retrospective chart review of 120 children found an association between early initiation of IV terbutaline and reduced respiratory failure, ICU admission, and mechanical ventilation. Injected β-agonists, subcutaneous terbutaline, and intramuscular epinephrine are recommended as a secondary bronchodilator primarily in a prehospital setting or suspected anaphylaxis. A recent Cochrane review shown that intravenous magnesium sulphate reduced hospital length of stay. It also found that Aminophylline increased vomiting compared to placebo, and increased nausea and nausea/vomiting compared to intravenous beta2-agonists.
- Participant
- We will assess studies that included children and adolescents aged 18 years and under, with acute severe asthma exacerbation.
- Animal
- Human Disease Modelled
- Intervention
- Interventions of the included studies would be the therapeutic use of IV aminophylline versus, IV SABA, versus IV magnesium sulphate, versus SC adrenaline, for treatment of acute severe asthma exacerbation.
- Comparator Control
- Comparison of the included studies would be the therapeutic use of IV aminophylline versus, IV SABA, versus IV magnesium sulphate, versus SC adrenaline, for treatment of acute severe asthma exacerbation.
- Main Outcome
- • Morbidity (symptoms, hospitalization, school absence). Measures of effect For dichotomous data, we will report the risk ratio (RR). The mean difference (MD) or standardized mean difference (SMD) will be calculated for continuous data.
- Outcome Measure
- Additional Outcome
- • Escalation of care (ventilation/PICU admission) • Length of hospital stay • Adverse events • Mortality due to exacerbation. Measures of effect For dichotomous data, we will report the risk ratio (RR). The mean difference (MD) or standardized mean difference (SMD) will be calculated for continuous data.
- Study Method
- Intervention, Meta-analysis, Systematic review
- Keyword
- 3-(2-(4-azidobenzamidino)ethyl)-5-hydroxyindole; Adolescent; Aminophylline; Asthma; Child; Epinephrine; Humans; Magnesium Sulfate; Randomized Controlled Trials as Topic; Status Asthmaticus
- Contact
- Ibtihal Abdelgadir [email protected]
- Organisational Affiliation
- NHS
- Funding Source
- Other Selection Criteria
- Final Publication
- Same Topic Review
- Published Protocol
- Review Type
- Language
- English
- Country
- Canada, England, Qatar, Wales
- Review Stage
- Review Ongoing
- First Submission Date
- 2023-03-05
- Registration Date
- 2023-03-06
- Anticipated Start Date
- 2023-05-01
- Anticipated Completion Date
- 2023-12-31
- Title Cn
- 二线治疗选择（静脉氨茶碱 vs. 静脉短效β2受体激动剂 vs. 静脉硫酸镁 vs. 皮下注射肾上腺素）用于儿童和青少年急性严重哮喘发作：随机对照试验的系统评价和Meta分析
- Title En
- Second line treatment options (IV aminophylline, versus IV short-acting-beta2-agonist (SABA), versus IV magnesium sulphate, versus SC adrenaline) for children and adolescents with an acute severe asthma exacerbation: a systematic review and meta-analyses of randomized controlled trials
- Bilingual Status
- complete